Browsing: Agonists

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Press release Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Analysis Highlights Growth To $32.86 Billion By 2030 At 16.2% CAGR 08-19-2026 12:56 PM CET | Health & MedicinePress release from: The Business Research Company Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market The market for glucagon-like peptide…

Background: The popularity of GLP-1 receptor agonists (GLP-1 RAs) for weight loss has increased significantly in recent years, raising concerns about self-medication with these medications. Objective: To assess the proportion and identify factors associated with GLP-1 RA use without medical prescription among GLP-1 RA users in Brazil. Methods: This cross-sectional study was conducted through a…

Social media has labelled GLP-1 receptor agonists as “miracle” weight-loss drugs. However, these medicines represent more than a passing trend. Obesity is a complex chronic disease often associated with diabetes, hypertension and cardiovascular problems. GLP-1 receptor agonists, initially developed for type 2 diabetes, now play an important role in obesity management

NEW real-world evidence shows that GLP-1 receptor agonists significantly reduce joint pain and inflammation in psoriatic arthritis. Patients living with psoriatic arthritis frequently experience a heavy metabolic disease burden, with concomitant obesity operating as a primary driver of heightened systemic inflammation, severe disease activity, and reduced response to biological therapies. To evaluate the therapeutic potential…

This is a paid press release. Contact the press release distributor directly with any enquiries.

My brother-in-law is a lovely man, but for years he’s suffered from obesity. He also gambles and drinks alcohol too much. I hesitate to get too involved, but I recently read that the new weight-loss drugs based on GLP-1 agonists are also helpful in reducing alcohol and gambling addictions. This sounds too good to be…

1 receptor agonists may reduce obesity related cancer risk through metabolic and direct cellular mechanisms, according to new evidence